Related Experiment Video
Updated: May 21, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
The burden of hyperkalaemia in chronic kidney disease: a systematic literature review
Jürgen Floege1, Andrew H Frankel2, Kevin F Erickson3
1Division of Nephrology and Dept of Cardiology, RWTH Aachen University, Aachen, Germany.
Insights
Hyperkalaemia in chronic kidney disease (CKD) patients is common and linked to adverse outcomes. Managing this condition, especially with renin-angiotensin-aldosterone system inhibitors (RAASi), requires careful consideration due to significant health and economic impacts.
Area of Science:
- Nephrology
- Pharmacology
- Public Health
Background:
- Hyperkalaemia is a common complication in chronic kidney disease (CKD) patients.
- Inconsistent definitions obscure the true global epidemiology and burden of hyperkalaemia.
- Understanding hyperkalaemia is crucial due to adverse effects and drug interactions, particularly with renin-angiotensin-aldosterone system inhibitors (RAASi).
Purpose of the Study:
- To systematically review and summarize evidence on hyperkalaemia risk factors in adult CKD patients.
- To describe characteristics associated with hyperkalaemia, including the impact of sub-optimal RAASi use.
- To explore the clinical and economic outcomes of hyperkalaemia in CKD.
Main Methods:
- Systematic literature review of Medline and Embase databases (2000-2024) with hand searching.
- Screening by two independent reviewers; data extraction and quality assessment by separate reviewers.
- Descriptive summarization of identified studies.
Main Results:
- 138 studies (145 publications) met eligibility criteria.
- Hyperkalaemia prevalence varies with definitions but is significantly increased in CKD patients, irrespective of RAASi treatment.
- Hyperkalaemia is associated with adverse outcomes, increased healthcare resource utilization, and negative economic impacts, particularly with sub-optimal RAASi dosing in CKD patients with or without heart failure.
Conclusions:
- This review provides a comprehensive overview of hyperkalaemia in CKD, focusing on clinical and economic outcomes.
- The interplay between hyperkalaemia risks and sub-optimal RAASi dosing necessitates further research.
- Clinicians must exercise caution when managing hyperkalaemia in CKD patients.
Background:
The global epidemiology and burden of hyperkalaemia in patients with chronic kidney disease (CKD) are unclear due to the inconsistent definitions of hyperkalaemia. The combination of adverse effects and interaction between comorbidity and pharmacotherapies, such as renin-angiotensin-aldosterone system inhibitors (RAASi), justify a systematic understanding of this common complication of CKD.
Methods:
This systematic literature review aimed to identify and descriptively summarize the evidence on hyperkalaemia risk factors and associated characteristics in adult CKD patients, including the effects of sub-optimal RAASi. Medline® and Embase® databases were searched from January 2000 to April 2024, with additional hand searching. Publications were screened by two independent reviewers. Data were extracted by one reviewer and verified by another reviewer; study quality assessment was also conducted.
Results:
A total of 138 studies described in 145 publications met the eligibility criteria. The published literature revealed varying prevalence of hyperkalaemia amongst inconsistent definitions and a significant increase in the prevalence and incidence of hyperkalaemia among patients with CKD, regardless of RAASi treatment. Hyperkalaemia was associated with adverse outcomes and increased hospital resource use. Additionally, studies pointed to negative health and economic outcomes due to sub-optimal RAASi dosing in CKD patients with hyperkalaemia, as well as in those with CKD and comorbid heart failure.
Conclusions:
This review expands on current research, offering a new perspective specifically focused on CKD patients and wider clinical and economic outcomes. Identification of wider clinical and economic consequences of hyperkalaemia in CKD patients, and the interplay between these risks and the risks of sub-optimal RAASi dosing, justify the need for future research. Clinicians should exercise caution when managing this condition in this complex patient group.
Related Concept Videos
Hormonal Regulation
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Diuretics
Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
The pKa of a...
Kidney Structure
Nephrons

